Study of a new treatment for people with PNH on Soliris
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests an investigational drug called NM8074 that may help people with paroxysmal nocturnal hemoglobinuria (PNH) who still have symptoms despite being on Soliris. It aims to see if the new drug is safe and effective when added or when switching from Soliris.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Are 18 years or older
- Have a confirmed PNH diagnosis with at least 5% of certain white blood cells affected
- Have had at least one PNH symptom (like fatigue, low blood counts, dark urine, blood clots, or needing transfusions) within the last 3 months
- Have been on Soliris (a medicine that helps protect blood cells) for at least 3 months, and have recent lab work showing high LDH (a sign of ongoing red blood cell breakdown)
- Are able to get vaccinated against meningococcal infection (or show proof you already have)
- Are not pregnant, planning pregnancy, or nursing (if female), and agree to use effective birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called SGB-9768 that may help people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that causes red blood cells to break down. The drug aims to control the disease and improve blood counts, which may reduce symptoms like fatigue and anemia.
This trial tests a new medicine, XH-S003, for people with paroxysmal nocturnal hemoglobinuria (PNH) who have not tried complement inhibitors before. The goal is to see if it can help manage symptoms like low red blood cells and fatigue.
This trial tests a new investigational drug called NM8074 for people with PNH whose disease is not well controlled on Soliris. It aims to see if this new treatment can improve their anemia and reduce the need for blood transfusions.
This trial tests an investigational drug called NM8074 for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not yet been treated with complement inhibitors. The goal is to see if NM8074 can reduce red blood cell destruction and improve anemia, potentially reducing the need for blood transfusions.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This trial tests a new drug, HS-10542, for people with PNH who are already on a C5 inhibitor like eculizumab or covalizumab but still have low hemoglobin or need transfusions. It aims to see if this additional treatment can improve blood counts and reduce transfusion needs.
Hear when a new PNH - Paroxysmal Nocturnal Hemoglobinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.